FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004361934> ?p ?o ?g. }

• W2004361934 endingPage "235" @default.
• W2004361934 startingPage "228" @default.
• W2004361934 abstract "Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of debate. To evaluate the antitumour activity of cabazitaxel in mCRPC pretreated with abiraterone or enzalutamide. The antitumour activity of cabazitaxel was assessed in patients with mCRPC and progressive disease after treatment with docetaxel and AA. In parallel, cabazitaxel antitumour activity was studied in enzalutamide-resistant models. Changes in prostate-specific antigen (PSA) levels and progression-free survival were used to determine the activity of cabazitaxel treatment. Cell proliferation, immunofluorescence, and AR transactivation assay were used in enzalutamide-resistant models. A total of 79 patients who had progressive mCRPC after docetaxel (median: 8 cycles; range: 4–12 mo), and AA (median: 4.8 mo; range:1–55 mo) received cabazitaxel 25 mg/m2 every 3 weeks (median: 6 cycles; range:1–15 cycles). A PSA decline ≥30% was achieved in 48 patients (62%; 95% confidence interval [CI], 51–73), and a decline ≥50% was achieved in 28 patients (35%; 95% CI, 25–47). The median progression-free survival and overall survival were 4.4 and 10.9 mo, respectively. In vitro, cabazitaxel decreased cell viability in both enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells within the same range of concentrations. PC3, an AR-negative cell line, exhibited similar sensitivity to cabazitaxel. Cabazitaxel and AR-pathway inhibitors are not cross-resistant. Preclinical data suggest that cabazitaxel activity does not act mainly through AR axis inhibition. The antitumour activity of cabazitaxel, a chemotherapy agent, was studied in prostate cancer resistant to conventional hormonal therapy and to more recent endocrine therapies (abiraterone or enzalutamide). Cabazitaxel retained anticancer activity in more than half of the cases." @default.
• W2004361934 created "2016-06-24" @default.
• W2004361934 creator A5007779528 @default.
• W2004361934 creator A5009585365 @default.
• W2004361934 creator A5019500272 @default.
• W2004361934 creator A5026180389 @default.
• W2004361934 creator A5027991868 @default.
• W2004361934 creator A5047931135 @default.
• W2004361934 creator A5051297483 @default.
• W2004361934 creator A5051902136 @default.
• W2004361934 creator A5062125605 @default.
• W2004361934 creator A5074162105 @default.
• W2004361934 creator A5084631227 @default.
• W2004361934 creator A5088300469 @default.
• W2004361934 creator A5090082356 @default.
• W2004361934 date "2015-08-01" @default.
• W2004361934 modified "2023-09-28" @default.
• W2004361934 title "Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies" @default.
• W2004361934 cites W1847958696 @default.
• W2004361934 cites W1969202480 @default.
• W2004361934 cites W1980244461 @default.
• W2004361934 cites W1996389184 @default.
• W2004361934 cites W2027596550 @default.
• W2004361934 cites W2030864103 @default.
• W2004361934 cites W2038621648 @default.
• W2004361934 cites W2075004958 @default.
• W2004361934 cites W2103959341 @default.
• W2004361934 cites W2106060738 @default.
• W2004361934 cites W2110534364 @default.
• W2004361934 cites W2118564089 @default.
• W2004361934 cites W2121023961 @default.
• W2004361934 cites W2123526148 @default.
• W2004361934 cites W2123629153 @default.
• W2004361934 cites W2123838638 @default.
• W2004361934 cites W2137467802 @default.
• W2004361934 cites W2140835621 @default.
• W2004361934 cites W2141454098 @default.
• W2004361934 cites W2148643283 @default.
• W2004361934 cites W2149936559 @default.
• W2004361934 cites W2151278366 @default.
• W2004361934 cites W2155273887 @default.
• W2004361934 cites W2162411576 @default.
• W2004361934 cites W2167331614 @default.
• W2004361934 cites W2168108459 @default.
• W2004361934 cites W2170668585 @default.
• W2004361934 doi "https://doi.org/10.1016/j.eururo.2014.04.015" @default.
• W2004361934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24837187" @default.
• W2004361934 hasPublicationYear "2015" @default.
• W2004361934 type Work @default.
• W2004361934 sameAs 2004361934 @default.
• W2004361934 citedByCount "136" @default.
• W2004361934 countsByYear W20043619342014 @default.
• W2004361934 countsByYear W20043619342015 @default.
• W2004361934 countsByYear W20043619342016 @default.
• W2004361934 countsByYear W20043619342017 @default.
• W2004361934 countsByYear W20043619342018 @default.
• W2004361934 countsByYear W20043619342019 @default.
• W2004361934 countsByYear W20043619342020 @default.
• W2004361934 countsByYear W20043619342021 @default.
• W2004361934 countsByYear W20043619342022 @default.
• W2004361934 countsByYear W20043619342023 @default.
• W2004361934 crossrefType "journal-article" @default.
• W2004361934 hasAuthorship W2004361934A5007779528 @default.
• W2004361934 hasAuthorship W2004361934A5009585365 @default.
• W2004361934 hasAuthorship W2004361934A5019500272 @default.
• W2004361934 hasAuthorship W2004361934A5026180389 @default.
• W2004361934 hasAuthorship W2004361934A5027991868 @default.
• W2004361934 hasAuthorship W2004361934A5047931135 @default.
• W2004361934 hasAuthorship W2004361934A5051297483 @default.
• W2004361934 hasAuthorship W2004361934A5051902136 @default.
• W2004361934 hasAuthorship W2004361934A5062125605 @default.
• W2004361934 hasAuthorship W2004361934A5074162105 @default.
• W2004361934 hasAuthorship W2004361934A5084631227 @default.
• W2004361934 hasAuthorship W2004361934A5088300469 @default.
• W2004361934 hasAuthorship W2004361934A5090082356 @default.
• W2004361934 hasConcept C121608353 @default.
• W2004361934 hasConcept C126322002 @default.
• W2004361934 hasConcept C126894567 @default.
• W2004361934 hasConcept C143998085 @default.
• W2004361934 hasConcept C2775832370 @default.
• W2004361934 hasConcept C2776551883 @default.
• W2004361934 hasConcept C2776694085 @default.
• W2004361934 hasConcept C2777511904 @default.
• W2004361934 hasConcept C2777899217 @default.
• W2004361934 hasConcept C2778971682 @default.
• W2004361934 hasConcept C2780192828 @default.
• W2004361934 hasConcept C2781190966 @default.
• W2004361934 hasConcept C502942594 @default.
• W2004361934 hasConcept C530470458 @default.
• W2004361934 hasConcept C61367390 @default.
• W2004361934 hasConcept C71924100 @default.
• W2004361934 hasConcept C98274493 @default.
• W2004361934 hasConceptScore W2004361934C121608353 @default.
• W2004361934 hasConceptScore W2004361934C126322002 @default.
• W2004361934 hasConceptScore W2004361934C126894567 @default.
• W2004361934 hasConceptScore W2004361934C143998085 @default.
• W2004361934 hasConceptScore W2004361934C2775832370 @default.
• W2004361934 hasConceptScore W2004361934C2776551883 @default.

• next